Etamsylate
[CAS# 2624-44-4]

Identification

• Classification: API >> Blood system medication >> Hemostatic drug
• Name: Etamsylate
• Synonyms: 2,5-Dihydroxybenzenesulfonic acid N-ethylethanamine
• Molecular Formula: C₆H₆O₅S.C₄H₁₁N
• Molecular Weight: 263.31
• CAS Registry Number: 2624-44-4
• EC Number: 220-090-7
• SMILES: CCNCC.C1=CC(=C(C=C1O)S(=O)(=O)O)O

Properties

• Solubility: 43 mM (DMSO) (Expl.)

Safety Data

• Hazard Symbols: GHS07 Warning
• Risk Statements: H319
• Safety Statements: P264+P265-P280-P305+P351+P338-P337+P317

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Eye irritation	Eye Irrit.	2	H319
Reproductive toxicity	Repr.	2	H361

Discovery and Applications

Etamsylate is a synthetic compound primarily used as a hemostatic agent, meaning it helps to control bleeding. Its chemical structure is based on an aromatic compound with a sulfonic acid ester functional group. It is commonly used in medical treatments to prevent or reduce bleeding, particularly in patients undergoing surgical procedures or those with conditions associated with abnormal bleeding.

The discovery of etamsylate dates back to the 1960s, when it was developed to address the need for a drug that could effectively control capillary bleeding without significant side effects. It works by improving the stability and function of blood vessels, specifically targeting the integrity of the capillaries, which are the smallest blood vessels in the body. Etamsylate helps to strengthen the walls of capillaries, thus reducing their tendency to break or leak, which leads to bleeding.

Etamsylate is typically used in the management of various types of bleeding, including those associated with surgery, trauma, or certain medical conditions. It is particularly useful in preventing or controlling bleeding from the small blood vessels (capillaries) and is commonly used in procedures such as dental extractions, minor surgeries, or gynecological procedures. In addition, it is often prescribed to patients experiencing excessive menstrual bleeding (menorrhagia) or bleeding related to other gynecological disorders.

The mechanism of action of etamsylate is related to its ability to stabilize the endothelial cells, which line the inside of blood vessels, and enhance platelet aggregation, a process crucial for blood clotting. This contributes to reduced bleeding and helps in wound healing. Etamsylate has a direct effect on the blood vessels and does not affect the coagulation cascade in the same way as other hemostatic agents like tranexamic acid or fibrinogen-based therapies.

Etamsylate is generally well-tolerated, with few side effects. However, as with any medication, side effects such as gastrointestinal disturbances, headache, or dizziness can occur in some individuals. It is considered a relatively safe medication when used as directed, though it should be avoided in patients with a known hypersensitivity to the drug or its components.

In addition to its hemostatic properties, etamsylate has been used in some cases for its ability to reduce the duration and severity of bleeding in conditions like thrombocytopathy, where platelet function is impaired. It is also used in the management of bleeding associated with certain medical conditions such as capillary fragility or excessive bruising.

Etamsylate is usually administered orally or intravenously, depending on the clinical situation. In its oral form, it is available as tablets, while intravenous administration may be used in more severe cases or when rapid action is required. The dosage and frequency of administration depend on the specific condition being treated and the severity of the bleeding.

In summary, etamsylate is a well-established hemostatic agent with a specific action on capillaries to prevent and manage bleeding. It is commonly used in medical and surgical settings to control minor to moderate bleeding, including in patients with conditions like menorrhagia. Its ability to stabilize blood vessel walls and enhance platelet aggregation makes it a valuable tool in clinical practice, particularly in procedures where bleeding is a concern.

References

1994. Treatment of superficial mycoses in the tropics: Whitfield's ointment versus clotrimazole. *International Journal of Dermatology*, 33(10).
DOI: 10.1111/j.1365-4362.1994.tb01524.x

1979. A comparison between the effects of nystatin, clotrimazole and miconazole on vaginal candidiasis. *BJOG: An International Journal of Obstetrics & Gynaecology*, 86(7).
DOI: 10.1111/j.1471-0528.1979.tb10812.x

1979. Superficial mycosis. Treatment with clotrimazole. Report of 60 cases. *Actas Dermo-Sifiliograficas*, 70(5-6).